AZD2389 free base · Synonyms: AZD-2389 · AZD 2389

AZD2389 is a potent and orally active FAP inhibitor.

For research use only. Not for human or veterinary use.

Target FAP

Research area Metabolic Disease

Purity >98% Stock Inquire

Data Sheet SDS COA

AZD2389 structure

CAS No.: 2791472-12-1

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
50 mg	USD 458.00	BP-02054-50mg	In stock	Get quote
100 mg	USD 650.00	BP-02054-100mg	In stock	Get quote
250 mg	USD 958.00	BP-02054-250mg	In stock	Get quote
500 mg	USD 1,358.00	BP-02054-500mg	In stock	Get quote
1 g	USD 1,880.00	BP-02054-1g	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Description

AZD2389 is a potent and orally active FAP inhibitor. AZD2389 can be used for the study of metabolic dysfunction-associated steatohepatitis .

Biological activity

In Vivo AZD2389 (29 week) increases intact α2-antiplasmin and improvements in non-alcoholic fatty liver disease (NAFLD) activity score and histological fibrosis in cynomolgus monkeys with diet induced, biopsy confirmed metabolic dysfunction-associated steatohepatitis (MASH) (F1/2 fibrosis).

Identifiers

SMILES: O=C(N1[C@@H](CSC1)C#N)CNC(C2=CC=NC3=C2C=C(N4CCOCC4)C=C3)=O
InChIKey: GECJKRWOVGXGCO-OAHLLOKOSA-N

Specifications

MW (average): 411.4770
Formula: C₂₀H₂₁N₅O₃S
CAS No.: 2791472-12-1
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO， >50 mg/mL

Documents

References

[1]. AZD2389, a first in class candidate drug for the treatment of metabolic dysfunction-associated steatohepatitis.

Same research area

Search Metabolic Disease